Toshiba releases Xpress/GX CT scanner
Toshiba America Medical Systems has released a new CT scannerthat moves the spiral scanning technology of the company's premiumXpress/SX scanner to a more compact package. Xpress/GX is a one-secondscanner that is 50% smaller and 30% lighter than most
Toshiba America Medical Systems has released a new CT scannerthat moves the spiral scanning technology of the company's premiumXpress/SX scanner to a more compact package. Xpress/GX is a one-secondscanner that is 50% smaller and 30% lighter than most systemson the market, according to the Tustin, CA, vendor.
Toshiba achieved space savings by incorporating the scanner'sx-ray generator into the gantry. The system also uses a new opticaldata transmission technology for transferring data from rotatingx-ray detectors to the display. Xpress/GX can be installed intoa 10 x 20-foot room and weighs just over 4100 pounds.
The scanner employs nearly 900 solid-state detectors, has aspatial resolution of 18 lp/cm and ships standard with a 3.5-million-heat-unit x-ray tube. It can resolve objects as smallas 2.5 mm at 0.25% contrast, and standard image reconstructiontakes five seconds. Xpress/GX will carry a list price of $890,000.
Toshiba's new scanners, including the Xpress/SX, have improvedthe company's CT market-share position this year, according toJohn Ariatti, vice president of marketing. Toshiba estimates itsU.S. market share at just under 10%, several points higher thanits share last year, Ariatti said.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
